Floatz logo

SUFENTANYL

Surgery

Peking University First HospitalSmall moleculePhase 4 / ApprovedActive
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
81/ 100

Competitive context

45 Active assets in the Surgery cohort.

Asset / SponsorPhaseRating
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Ain Shams University
Phase 4BB
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
University of California, Davis
Phase 4BB
ROPIVACAINE
Claus Anders Bertelsen, PhD, MD
Phase 4BB
PROPOFOL
Samsung Medical Center
Phase 4BB
Ferric Carboxymaltose [Ferinject]
Jon Unosson
Phase 4BB

View all 50 →

Same molecule, other indications

SUFENTANYL is also rated in:

chronic pain syndromeDormant
BB
Indicative ·
69 / 100
View asset →
AnalgesicsDormant
BB
Indicative ·
68 / 100
View asset →
Post Operative PainDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →